

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: TM3/22 - Tumour Markers

Deadline: 26.07.2022

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(208) beta-2-microglobulin</b>					11							10	10	100%
— Samples and groups	[mg/L]													
<b>Sample A</b>		1,32	0,18	14	11							10	10	100%
Other					11	0						10		
							1x 4/29, 1x 6/1, 1x 6/58, 3x 6/60, 1x 6/75, 1x 6/91, 1x 6/149, 1x 6/162, 1x 6/179							
<b>Sample B</b>		4,72	0,21	4,4	11							10	10	100%
Other					11	0						10		
							1x 4/29, 1x 6/1, 1x 6/58, 3x 6/60, 1x 6/75, 1x 6/91, 1x 6/149, 1x 6/162, 1x 6/179							
<b>(185) AFP</b>					12							12	11	92%
— Samples and groups	[µg/L]													
<b>Sample A</b>		21,6	2,0	9,3	12							12	11	92%
Other					12	0						12		
							4x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>Sample B</b>		30,4	2,0	6,5	12							12	11	92%
Other					12	0						12		
							4x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>(181) CA 15-3</b>					11							11	10	91%
— Samples and groups	[kU/L]													
<b>Sample A</b>		35,0	6,0	17	11							11	10	91%
Other					11	0						11		
							4x 4/1, 1x 4/12, 4x 4/60, 1x 4/162, 1x 4/179							
<b>Sample B</b>		12,7	1,9	15	11							11	11	100%
Other					11	0						11		
							4x 4/1, 1x 4/12, 4x 4/60, 1x 4/162, 1x 4/179							
<b>(182) CA 19-9</b>					12							12	12	100%
— Samples and groups	[kU/L]													
<b>Sample A</b>		6,40	2,1	32	12							12	12	100%
Other					12	0						12		
							4x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>Sample B</b>		134	110	82	12							12	12	100%
Other					12	0						12		
							4x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>(183) CA 72-4</b>					11							11	10	91%
— Samples and groups	[kU/L]													
<b>Sample A</b>		2,17	0,17	7,8	11							11	11	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		2,17	0,17	7,8	11	0	CVPG	2,09	0,027	22%	1,63	2,55	11	
(60) Roche														
<b>Sample B</b>		10,1	0,85	8,4	11							11	10	91%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		10,1	0,85	8,4	11	0	CVPG	10,7	0,21	22%	8,34	13,1	11	
(60) Roche														
<b>(180) CA 125</b>					12							12	12	100%
— Samples and groups	[kU/L]													
<b>Sample A</b>		11,0	1,7	16	12							12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		12,6	0,37	3,0	5	0	CVPG	12,8	0,19	20%	10,2	15,4	5	
(1) Abbott														
Other					7	0						7		
							1x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>Sample B</b>		10,1	1,6	16	12							12	12	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		11,5	0,22	1,9	5	0	CVPG	11,7	0,18	20%	9,36	14,1	5	
(1) Abbott														
Other					7	0						7		
							1x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>(189) CEA</b>					12							12	12	100%
— Samples and groups	[µg/L]													
<b>Sample A</b>		12,2	1,6	13	12							12	12	100%
Other					12	0						12		
							4x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>Sample B</b>		18,9	2,6	14	12							12	12	100%
Other					12	0						12		
							4x 4/1, 2x 4/12, 3x 4/60, 1x 4/162, 2x 4/179							
<b>(184) CYFRA 21-1</b>					11							11	9	82%
— Samples and groups	[µg/L]													
<b>Sample A</b>		1,05	0,32	30	11							11	10	91%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		1,21	0,13	11	8	0	CVPG	1,09	0,026 ± 0,24	0,856	1,33	8		
(60) Roche														
Other					3	0						3		
							3x 4/1							
<b>Sample B</b>		15,0	1,5	10	11							11	10	91%

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

## EQA round: TM3/22 - Tumour Markers

Deadline: 26.07.2022

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(184) CYFRA 21-1</b>					11							11	9	82%
Samples and groups	[µg/L]													
<b>Sample B</b>		15,0	1,5	10	11							11	10	91%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		15,7	0,53	3,3	8	0	CVPG	15,1	0,15	18%	12,3	17,9	8	
(60) Roche														
Other					3	0							3	
							3x 4/1							
<b>(186) hCG</b>					13							10	9	90%
Samples and groups	[U/L]													
<b>Sample A</b>		104	16	15	13							10	9	90%
Other					13	0							10	
							1x 4/1, 2x 4/12, 1x 4/58, 4x 4/60, 1x 4/162, 2x 4/179, 2x 4/210							
<b>Sample B</b>		1,27	0,58	45	13							10	10	100%
Other					13	0							10	
							1x 4/1, 2x 4/12, 1x 4/58, 4x 4/60, 1x 4/162, 2x 4/179, 2x 4/210							
<b>(206) Calcitonin</b>					2							2	1	50%
Samples and groups	[ng/L]													
<b>Sample A</b>		32,2	4,1	13	2							2	2	100%
Other					2	0							2	
							1x 4/29, 1x 4/60							
<b>Sample B</b>		27,2	4,2	15	2							2	1	50%
Other					2	0							2	
							1x 4/29, 1x 4/60							
<b>(194) NSE</b>					12							11	11	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		72,6	5,9	8,2	12							11	11	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		73,3	5,2	7,1	11	0	CVPG	70,5	0,76	30%	49,3	91,7	11	
(60) Roche														
Other					1	0								0
							1x 4/1							
<b>Sample B</b>		5,33	0,68	13	12							11	11	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		5,39	0,69	13	11	0	CVPG	5,53	0,10	30%	3,87	7,19	11	
(60) Roche														
Other					1	0								0
							1x 4/1							
<b>(191) PSA</b>					11							11	10	91%
Samples and groups	[µg/L]													
<b>Sample A</b>		10,8	2,1	19	11							11	10	91%
Other					11	0							11	
							3x 4/1, 1x 4/12, 3x 4/60, 1x 4/162, 2x 4/179, 1x 4/195							
<b>Sample B</b>		3,33	0,51	15	11							11	10	91%
Other					11	0							11	
							3x 4/1, 1x 4/12, 3x 4/60, 1x 4/162, 2x 4/179, 1x 4/195							
<b>(198) free-PSA</b>					8							8	8	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		8,23	1,5	18	8							8	8	100%
Other					8	0							8	
							3x 4/1, 2x 4/60, 2x 4/179, 1x 4/195							
<b>Sample B</b>		2,32	0,33	14	8							8	8	100%
Other					8	0							8	
							3x 4/1, 2x 4/60, 2x 4/179, 1x 4/195							
<b>(201) S-100</b>					6							6	6	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		0,467	0,025	5,4	6							6	6	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		0,467	0,025	5,4	6	0	CVPG	0,468	,0071	32%	0,318	0,618	6	
(60) Roche														
<b>Sample B</b>		0,038	0,003	7,9	6							6	6	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI);		0,038	0,003	7,9	6	0	CVPG	0,04		±0,013	0,027	0,053	6	
(60) Roche														
<b>(195) SCCA</b>					7							7	7	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		4,55	0,37	8,1	7							7	7	100%
Other					7	0							7	
							4x 4/1, 3x 4/60							
<b>Sample B</b>		2,19	0,17	7,8	7							7	7	100%
Other					7	0							7	
							4x 4/1, 3x 4/60							
<b>(207) Thyreoglobulin</b>					4							4	4	100%
Samples and groups	[µg/L]													
<b>Sample A</b>		96,9	5,0	5,2	4							4	4	100%
Other					4	0							4	
							1x 4/12, 3x 4/60							
<b>Sample B</b>		45,2	4,9	11	4							4	4	100%
Other					4	0							4	
							1x 4/12, 3x 4/60							

